Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
How Eli Lilly’s CEO Plans to Defeat Pharma’s Boom-Bust Cycle
Posted
June 23, 2026
Views
1,652
Likes
13
Comments
3
Engagement
June 23, 2026
1,652
13
3
0.97%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
6:05Now PlayingWhen Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege.
Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly’s 150-year history, concedes that one was a public-relations nightmare.
Almost a decade later, the mood at Lilly has shifted dramatically. The company’s hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Saturday & Sunday 7am-10am ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
